Lineage Cell Therapeutics (LCTX) FCF Margin (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly FCF Margin of 471.48% for Q1 2026, down 13972.0% year-over-year from N/an in Q1 2025, and down 479.63% quarter-over-quarter from 81.34% in Q4 2025.
Powered by 
Analysis
Lineage Cell Therapeutics (LCTX) FCF Margin (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' FCF Margin history runs 17 years deep, the most recent figure standing at 471.48% for Q1 2026.
- In Q1 2026, FCF Margin fell 13972.0% year-over-year to 471.48%; the TTM figure through Mar 2026 stood at 152.86% (up 8591.0% YoY), while the FY2025 annual figure was 133.56%, up 11549.0% from the prior year.
- FCF Margin for Q1 2026 stood at 471.48%, down from 81.34% in the prior quarter.
- The five-year high for FCF Margin was 417.38% in Q1 2022, with the low at 477.58% in Q1 2023.
- The 5-year median for FCF Margin is 240.59% (2024), against an average of 240.06%.
- The sharpest annual moves came in 2022 and 2023: FCF Margin surged 231891 bps in 2022, then sank 89495 bps in 2023.
- Lineage Cell Therapeutics' FCF Margin stood at 412.64% in 2022, then gained by 29 bps to 292.62% in 2023, then gained by 18 bps to 240.59% in 2024, then soared by 66 bps to 81.34% in 2025, then plunged by 480 bps to 471.48% in 2026.
- Business Quant data shows LCTX's FCF Margin at 471.48% in Q1 2026, 81.34% in Q4 2025, and 95.9% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Lineage Cell Therapeutics | 270.71 Mn | 213.99 Mn | 1.07 Mn | -686.34% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -686.34% |
| Mar 31, 2026 | -472.35% |
| Dec 31, 2025 | -79.86% |
| Sep 30, 2025 | -98.56% |
| Jun 30, 2025 | -200.83% |
| Mar 31, 2025 | -331.76% |
| Dec 31, 2024 | -234.00% |
| Sep 30, 2024 | -156.10% |
| Jun 30, 2024 | -371.16% |
| Mar 31, 2024 | -403.12% |
| Dec 31, 2023 | -292.62% |
| Sep 30, 2023 | -415.41% |
| Jun 30, 2023 | -202.29% |
| Mar 31, 2023 | -479.04% |
| Dec 31, 2022 | -432.74% |
| Sep 30, 2022 | -192.33% |
| Jun 30, 2022 | -157.24% |
| Mar 31, 2022 | 417.38% |
| Dec 31, 2021 | -12.04% |
| Sep 30, 2021 | -215.95% |